This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Fresenius Medical Care AG & Co. KGaA (0H9X) Gets a Buy from DZ BANK AG
In a report released on March 13, from DZ BANK AG maintained a Buy rating on Fresenius Medical Care AG & Co. KGaA. The company’s shares closed last Friday at €39.78.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fresenius Medical Care AG & Co. KGaA has an analyst consensus of Hold, with a price target consensus of €39.13.
Based on Fresenius Medical Care AG & Co. KGaA’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €5.07 billion and a net profit of €327 million. In comparison, last year the company earned a revenue of €5.08 billion and had a net profit of €66.91 million
Read More on GB:0H9X:
Disclaimer & DisclosureReport an Issue
- Fresenius Medical price target lowered to EUR 42 from EUR 44 at Deutsche Bank
- Fresenius Medical price target lowered to EUR 34 from EUR 36 at Morgan Stanley
- Fresenius Medical reports Q4 EPS ex-items EUR1.44 vs. EUR0.91 last year
- Fresenius Medical sees 2026 revenue growth flat vs. EUR19.63B in 2025
- Sell Rating on Fresenius Medical Care Amid Unsustainable Earnings Quality and Structural Headwinds
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
